Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity

Author(s): Erin W Tuplin*, Matthew R Holahan*

Journal Name: Current Neuropharmacology

Volume 15 , Issue 8 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) are a common occurrence. Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and negative symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.

Objective: To identify evidence in the literature that elucidates the pharmacological profile of aripiprazole.s.

Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clinical efficacy, side-effects, pharmacology, and effects in animal models of schizophrenia symptoms.

Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacological profile, including partial D2 agonism and functionally selective properties. Aripiprazole is effective at treating the positive symptoms of schizophrenia and has the potential to treat negative and cognitive symptoms at least as well as other atypical antipsychotics. The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes. Animal models of schizophrenia have been used to determine the efficacy of aripiprazole in symptom management. In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal. Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clinically active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.

Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms. This review examines these mechanisms of action to further clarify the pharmacological actions of aripiprazole.

Keywords: Dopamine receptors, schizophrenia, antipsychotics, partial agonism, functional selectivity, serotonin receptors, MK-801

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 14 November, 2017
Page: [1192 - 1207]
Pages: 16
DOI: 10.2174/1570159X15666170413115754
Price: $65

Article Metrics

PDF: 58
PRC: 1